Virtual ACC 2020 | More Evidence in Support of the Demanding 2017 Hypertension Guidelines

It’s been a while since the demanding and tough 2017 document written jointly between ACC and AHA where, with much controversy, cutoff hypertension values were taken to extreme limits. In fact, more flexible ESC guidelines came out a few months later.

Despite this document, hypertension-related cardiovascular death kept increasing in the US across all age subgroups and regions. 

Results from the present analysis are along the line of prior observational studies. The downward trend in cardiovascular mortality has been slowing down while death for cardiac failure has begun to climb. 

Data to be presented by Dr. Nambiar at the frustrated ACC 2020, to be published simultaneously in JACC, show death for hypertension adjusted by age every 100.000 persons has risen from 18.3 in 2007 to 23 in 2017 (p<0.001 for this trend).


Read also: Virtual ACC 2020 | Myocardial Ischemia Induced by Sudden Mental Stress.


During this same period, cardiovascular death related to hypertension increased 72% in rural US vs 20% in cities (p<0.001 for this trend).

Mortality has increased across all age groups, with the highest impact in people ranging from 65 to 74, for both sexes, but mostly for men.


Read also: Virtual ACC 2020 | “Dangerous” Plaques by CT Effectively Predict Infarction.


The reasons behind this increase are multiple, but clearly diabetes and hypertension epidemics weigh on.

Adjusting to the new cutoff values set in 2017 seems critical.

Original title: Decade long temporal trends in U.S. hypertension related cardiovascular mortality.

Reference: Nambiar L et al. J Am Coll Cardiol. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...